Last Updated : June 13, 2022
Alzheimer disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. The cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine are first-line treatments for mild to moderate AD.
This project was conducted to measure the utilization of ChEIs and determine prescribing patterns and expenditures in Canada from 2017 to 2020. The utilization of ChEIs may give an indication of the future use of drug products for the treatment of AD that are in clinical development.